Editorial

We celebrate the sixth year since we started Oncology Gastroenterology and Hepatology Reports as a humble attempt to provide an unbiased platform for novel biomedical research and clinical findings.

The current issue of the journal includes a randomized uncontrolled clinical trial of anthelminthics for Ascaris infection from India. In this study, 400 patients, 63% of whom were between 5-19 years of age were randomized to receive albendazole, mebendazole, pyrantel pamoate or ivermectin. After 3 weeks, 92% of those who received albendazole had no detectable ova in stool. By comparison, 88% of those receiving mebendazole, 84% of those receiving pyrantel pamoate and 76% of those who received ivermectin had no detectable parasite eggs in stool. There were no significant adverse effects. Males were twice as commonly affected as females. Nearly 74% lived in rural areas and 90% were middle or low income group. Read more. . .